17316
document
Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes . Statins and fibrates influence endothelial activity and consequently atherogenesis but the mechanisms are not well understood . Twenty Type 2 diabetic patients with dyslipidemia were treated 3 months with simvastatin ( 20 mg daily ) and then 3 months with fenofibrate ( 200 mg daily ) with 2 months of wash-out between the two treatments . Laboratory parameters of oxidative stress , fibrinolysis and endothelial function were evaluated before and at the end of each treatment period . The significant decrease in serum total and LDL-cholesterol concentrations ( P < 0.0001 ) caused by simvastatin was associated with an increase in serum N-acetyl-beta-glucosaminidase activity ( P < 0.001 ) , ascorbic acid ( P < 0.001 ) , plasminogen activator inhibitor ( PAI-1 ) ( P < 0.01 ) , vonWillebrand factor ( P < 0.05 ) , E-selectin ( P < 0.01 ) and vascular endothelial growth factor ( P < 0.05 ) concentrations and with a decrease in plasma glutathione ( P < 0.01 ) levels . Fenofibrate caused a significant decrease in serum triglyceride concentration ( P < 0.0001 ) associated with a decrease in plasma malondialdehyde ( P < 0.001 ) and an increase in plasma PAI-1 ( P < 0.05 ) and P-selectin ( P < 0.05 ) concentrations . We conclude that simvastatin and fenofibrate interact , by different mechanisms , with oxidative stress , a key factor in the modification of fibrinolysis and endothelial function in Type 2 diabetes .
17317
Intervention_Pharmacological
simvastatin
17318
Intervention_Pharmacological
fenofibrate
17319
Intervention_Pharmacological
simvastatin
17320
Intervention_Pharmacological
fenofibrate
17321
Outcome_Physical
serum total and LDL-cholesterol concentrations
17322
Outcome_Physical
serum N-acetyl-beta-glucosaminidase activity
17323
Outcome_Physical
ascorbic acid
17324
Outcome_Physical
plasminogen activator inhibitor
17325
Outcome_Physical
vonWillebrand factor
17326
Outcome_Physical
E-selectin
17327
Outcome_Physical
vascular endothelial growth factor
17328
Outcome_Physical
plasma glutathione
17329
Outcome_Physical
serum triglyceride concentration
17330
Outcome_Physical
plasma malondialdehyde
17331
Outcome_Physical
plasma PAI-1
17332
Outcome_Physical
P-selectin
17333
Participant_Condition
Type 2 diabetes
17334
Participant_Sample-size
Twenty
17335
Participant_Condition
Type 2 diabetic patients with dyslipidemia